FDA may, for good cause, extend this 30-day period. Reconsideration of a denial may be sought only by the applicant; in these cases, the 30-day period will begin when the applicant is notified by FDA in writing of its decision.

The regulations provide that FDA publish a quarterly list of available safety and effectiveness summaries of PMA approvals and denials that were announced during that quarter. The following is a list of approved PMAs for which summaries of safety and effectiveness were placed on the Internet from January 1, 2010, through March 31, 2010. There were no denial actions during this period. The list provides the manufacturer’s name, the product’s generic name or the trade name, and the approval date.

### TABLE 1—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM JANUARY 1, 2010, THROUGH MARCH 31, 2010

<table>
<thead>
<tr>
<th>PMA No.</th>
<th>Docket No.</th>
<th>Applicant</th>
<th>Trade Name</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>P060040/S005</td>
<td>FDA–2010–M–0078</td>
<td>Thoratec Corp.</td>
<td>THORATEC HEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM (LVAS)</td>
<td>January 20, 2010</td>
</tr>
<tr>
<td>H080002</td>
<td>FDA–2010–M–0063</td>
<td>Medtronic, Inc.</td>
<td>MEDITRONIC MELODY TRANSCATHETER PULMONARY VALVE (MODEL PB10) AND MEDITRONIC ENSEMBLE TRANSCATHETER VALVE DELIVERY SYSTEM (NU10)</td>
<td>January 25, 2010</td>
</tr>
<tr>
<td>P090003</td>
<td>FDA–2010–M–0135</td>
<td>Boston Scientific Corp.</td>
<td>EXPRESS LD LLIAC PREMOUNTED STENT SYSTEM</td>
<td>March 5, 2010</td>
</tr>
<tr>
<td>P090006</td>
<td>FDA–2010–M–0158</td>
<td>Medtronic Vascular</td>
<td>COMPLETE SE VASCULAR STENT SYSTEM</td>
<td>March 17, 2010</td>
</tr>
</tbody>
</table>

II. Electronic Access

Persons with access to the Internet may obtain the documents at http://www.fda.gov/cdrh/pmapage.html.

Dated: June 28, 2010.

Nancy Stade,
Acting Associate Director for Regulations and Policy, Center for Devices and Radiological Health.

[FR Doc. 2010–16139 Filed 7–1–10; 8:45 am]
BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel ZAA1 HH01—AA3 Member Conflicts.

Date: July 30, 2010.

Time: 11 a.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892.

Contact Person: Lorraine Gunzerath, PhD, MBA, Scientific Review Officer, National Institute on Alcohol Abuse and Alcoholism, Office of Extramural Activities, Extramural Project Officer, 5635 Fishers Lane, Room 2121, Bethesda, MD 20892–3304, 301–443–2369.

(Catalogue of Federal Domestic Assistance Program Nos.)


Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010–16037 Filed 7–1–10; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS–1571–N]

Medicare Program; Second Semi-Annual Meeting of the Advisory Panel on Ambulatory Payment Classification Groups—August 23 & 24, 2010

AGENCY: Centers for Medicare & Medicaid Services, Department of Health and Human Services.

ACTION: Notice.

SUMMARY: This notice announces the second semi-annual meeting of the Advisory Panel on Ambulatory Payment Classification (APC) Groups (the Panel) for 2010. The purpose of the Panel is to review the APC groups and their associated weights and to advise the Secretary of the Department of Health and Human Services (DHHS) (the Secretary) and the Administrator of the Centers for Medicare & Medicaid Services (CMS) (the Administrator) concerning the clinical integrity of the APC groups and their associated weights. We will consider the Panel’s advice as we prepare the final rule that would update the hospital Outpatient Prospective Payment System (OPPS) for CY 2011.

DATES: Meeting Dates: We are scheduling the second semi-annual